Oncotarget

Clinical Research Papers:

Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study

Bin Zhang _, Ying Hu, Rui-Hua Xiong, Yu-Fei Pan, Qian-Lan Xu, Xiang-Yun Kong, Rui Cai, Qiu-Qiu Chen, Hua-Ying Tang and Wei Jiang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:14078-14088. https://doi.org/10.18632/oncotarget.13285

Metrics: PDF 1534 views  |   HTML 2064 views  |   ?  


Abstract

Bin Zhang1,2,*, Ying Hu1,*, Rui-Hua Xiong3,*, Yu-Fei Pan4,*, Qian-Lan Xu1, Xiang-Yun Kong1, Rui Cai1, Qiu-Qiu Chen1, Hua-Ying Tang1 and Wei Jiang1

1 Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, PR China

2 Department of Radiation Oncology, Wuzhou Red Cross Hospital, Wuzhou, PR China

3 Department of Radiation Oncology, 181st Hospital of People’s Liberation Army, Guilin, PR China

4 Department of Radiation Oncology, Nan Xishan Hospital, Guilin, PR China

* These authors have contributed equally to this work

Correspondence to:

Wei Jiang, email:

Keywords: nasopharyngeal carcinoma, induction chemotherapy, radiotherapy, concurrent chemoradiotherapy

Received: June 09, 2016 Accepted: October 12, 2016 Published: November 10, 2016

Abstract

Background: The relative efficacy of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) versus IC followed by radiotherapy (RT) alone in locoregionally advanced NPC remains unclear.

Methods: A total of 877 patients with locally advanced NPC who underwent IC/CCRT or IC/RT at four institutions in China between January 2004 and December 2010 were retrospectively assessed. IC was cisplatin-based combination chemotherapy; concurrent chemotherapy, single agent cisplatin. Two-dimensional conventional radiotherapy (2DCRT) was the radiotherapy technique. All patients were matched in an equal ratio using a pair-matched method. Overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRRFS) and toxicities were assessed.

Results: Eligible patients were matched (n = 642; 321 patients per arm) based on eight clinicopathological characteristics. Five-year OS, DFS, DMFS, and LRRFS were 76%, 70%, 86%, and 88% for IC/CCRT and 75%, 70%, 90%, and 91% for IC/RT, respectively. There were no statistically significant survival differences between arms (P>0.05), even in subgroup analysis. In multivariate analysis, treatment (IC/CCRT vs. IC/RT) was not an independent prognostic factor for any survival end-point. Grade 3/4 acute gastrointestinal toxicities (vomiting, nausea) and hematological toxicities (leucopenia/neutropenia, thrombocytopenia and anemia) were significantly more common in the IC/CCRT arm than IC/RT arm during RT.

Conclusion: Overall, IC/CCRT failed to demonstrate any survival advantage but higher acute toxicities over IC/RT in locoregionally advanced NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13285